Pharmacological Chaperone Therapy for Lysosomal Storage Diseases

References

• Balch WE , MorimotoRI, DillinAet al. Adapting proteostasis for disease intervention. Science319, 916–919 (2008).
   PubMed Web of Science ®Google Scholar
• Gomes CM . Protein misfolding in disease and small molecule therapies. Curr. Top. Med. Chem.12 (22), 2460–2469 (2012).
   PubMed Web of Science ®Google Scholar
• Cheng B , GongH, XiaoHet al. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Biochim. Biophys. Acta1830 (10), 4860–4871 (2013).
   PubMed Web of Science ®Google Scholar
• Powers ET , MorimotoRI, DillinAet al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem.78, 959–991 (2009).
   PubMed Web of Science ®Google Scholar
• Ong DS , KellyJW. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr. Opin. Cell Biol.23 (2), 231–238 (2011).
   PubMed Web of Science ®Google Scholar
• Wang F , SongW, BrancatiGet al. Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J. Biol. Chem.286 (50), 43454–43464 (2011).
   PubMed Web of Science ®Google Scholar
• Mu TW , OngDS, WangYJet al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell134 (5), 769–781 (2008).
   PubMed Web of Science ®Google Scholar
• Song W , WangF, SaviniMet al. TFEB regulates lysosomal proteostasis. Hum. Mol. Genet.22 (10), 1994–2009 (2013).
   PubMed Web of Science ®Google Scholar
• Brown CR , Hong-BrownLQ, BiwersiJet al. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones1 (2), 117–125 (1996).
   PubMed Web of Science ®Google Scholar
• Brown CR , Hong-BrownLQ, WelchWJ. Strategies for correcting the delta F508 CFTR protein-folding defect. J. Bioenerg. Biomembr.29 (5), 491–502 (1997).
   PubMed Web of Science ®Google Scholar
• Morello JP , SalahpourA, LaperrièreAet al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest.105 (7), 887–895 (2000).
   PubMed Web of Science ®Google Scholar
• Fan JQ , IshiiS, AsanoNet al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med.5 (1), 112–115 (1999).
   PubMed Web of Science ®Google Scholar
• Sawkar AR , ChengWC, BeutlerEet al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA99 (24), 15428–15433 (2002).
   PubMed Web of Science ®Google Scholar
• Cox TM , Cachón-GonzálezMB. The cellular pathology of lysosomal diseases. J. Pathol.226 (2), 241–254 (2012).
   PubMed Web of Science ®Google Scholar
• Ballabio A , GieselmannV. Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta1793 (4), 684–696 (2009).
   PubMed Web of Science ®Google Scholar
• Fuller M , MeiklePJ, HopwoodJJ. Epidemiology of lysosomal storage diseases: an overview. In :  Fabry Disease: Perspectives from 5 Years of FOS.MehtaA, BeckM, Sunder-PlassmannG  (Eds).  Oxford PharmaGenesis, Oxford, UK  (2006). www.ncbi.nlm.nih.gov/books/NBK11603
   Google Scholar
• Pastores GM , BarnettNL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin. Emerg. Drugs10 (4), 891–902 (2005).
   PubMedGoogle Scholar
• Lombard V , Golaconda RamuluH, DrulaE, CoutinhoPM, HenrissatB. The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res.42 (1), D490–D495 (2014).
   PubMedGoogle Scholar
• Dvir H , HarelM, McCarthy, Aet al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep.4 (7), 704–709 (2003).
   PubMed Web of Science ®Google Scholar
• Brumshtein B , WormaldMR, SilmanIet al. Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr. D Biol. Crystallogr.62 (12), 1458–1465 (2006).
   PubMedGoogle Scholar
• Pasmanik-Chor M , LaadanS, Elroy-SteinOet al. The glucocerebrosidase D409H mutation in Gaucher disease. Biochem. Mol. Med.59 (2), 125–133 (1996).
   PubMedGoogle Scholar
• Wei RR , HughesH, BoucherSet al. X-ray and biochemical analysis of N370S mutant human acid β-glucosidase. J. Biol. Chem.286 (1), 299–308 (2011).
   PubMed Web of Science ®Google Scholar
• Ron I , HorowitzM. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet.14 (16), 2387–2398 (2005).
   PubMed Web of Science ®Google Scholar
• Lu J , ChiangJ, IyerRRet al. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc. Natl Acad. Sci. USA107 (50), 21665–21670 (2010).
   PubMed Web of Science ®Google Scholar
• Garman Sc , GarbocziDn. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J. Mol. Biol.337 (2), 319–335 (2004).
   PubMed Web of Science ®Google Scholar
• Siekierska A , De BaetsG, ReumersJet al. Alpha-galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J. Biol. Chem.287 (34), 28386–28397 (2012).
   PubMed Web of Science ®Google Scholar
• Bruckmann C , RepoH, KuokkanenEet al. Systematic structure-activity study on potential chaperone lead compounds for acid alpha-glucosidase. ChemMedChem7 (11), 1943–1953 (2012).
   PubMed Web of Science ®Google Scholar
• Sugawara K , SaitoS, SekijimaMet al. Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease. J. Hum. Genet.54 (6), 324–330 (2009).
   PubMed Web of Science ®Google Scholar
• Rivera-Colón Y , SchutskyEK, KitaAZet al. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J. Mol. Biol.423 (5), 736–751 (2012).
   PubMed Web of Science ®Google Scholar
• Feldhammer M , DurandS, PshezhetskyAV. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS ONE4 (10), e7434 (2009).
   PubMed Web of Science ®Google Scholar
• Ficko-Blean E , StubbsKa, NemirovskyOet al. Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc. Natl Acad. Sci. USA105 (18), 6560–6565 (2008).
   PubMed Web of Science ®Google Scholar
• Yogalingam G , WeberB, MeehanJet al. Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant alpha-N-acetylglucosaminidase and relationship with Sanfilippo phenotype in an attenuated patient. Biochim. Biophys. Acta1502 (3), 415–425 (2000).
   PubMed Web of Science ®Google Scholar
• Bie H , YinJ, HeXet al. Insights into mucopolysaccharidosis I from the structure and action of alpha-L-iduronidase. Nat. Chem. Biol.9 (11), 746 (2013).
   PubMed Web of Science ®Google Scholar
• Walus M , KidaE, GolabekAA. Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I. Hum. Mutat.31 (6), 710–721. (2010).
   PubMed Web of Science ®Google Scholar
• Lemieux MJ , MarkBL, CherneyMMet al. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. J. Mol. Biol.359 (4), 913–929 (2006).
   PubMed Web of Science ®Google Scholar
• Maier T , StraterN, SchuetteCget al. The x-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease. J. Mol. Biol.328 (3), 669–681 (2003).
   PubMed Web of Science ®Google Scholar
• Tropak MB , ReidSP, GuiralMet al. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J. Biol. Chem.279 (14), 13478–13487 (2004).
   PubMed Web of Science ®Google Scholar
• Ohto U , UsuiK, OchiTet al. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases. J. Biol. Chem.287 (3), 1801–1812 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang S , BagshawR, HilsonWet al. Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis. Biochem. J.348 (Pt 3), 621–632 (2000).
   PubMedGoogle Scholar
• Lee WC , KangD, CausevicEet al. Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. J. Neurosci.30 (16), 5489–5497 (2010).
   PubMed Web of Science ®Google Scholar
• Clark NE , GarmanSC. The 1.9 a structure of human alpha-N- acetylgalactosaminidase: the molecular basis of Schindler and Kanzaki diseases. J. Mol. Biol.393 (2), 435–347 (2009).
   PubMed Web of Science ®Google Scholar
• Benjamin ER , FlanaganJJ, SchillingAet al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J. Inherit. Metab. Dis. 32 (3), 424–440 (2009).
   PubMed Web of Science ®Google Scholar
• Young-Gqamana B , BrignolN, ChangHHet al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE 8 (3), e57631 (2013).
   PubMed Web of Science ®Google Scholar
• Sawkar AR , ChengWC, BeutlerEet al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci USA 99 (24), 15428–15433 (2002).
   PubMed Web of Science ®Google Scholar
• Steet RA , ChungS, WustmanB, PoweA, DoH, KornfeldSA. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl Acad. Sci. USA103 (37), 13813–13818 (2006).
   PubMed Web of Science ®Google Scholar
• Khanna R , BenjaminER, PellegrinoLet al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J. 277 (7), 1618–1638 (2010).
   PubMed Web of Science ®Google Scholar
• Sun Y , LiouB, XuYHet al. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J. Biol. Chem.287 (6), 4275–4287 (2012).
   PubMed Web of Science ®Google Scholar
• Bendikov-Bar I , MaorG, FilocamoMet al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50 (2), 141–145 (2013).
   PubMed Web of Science ®Google Scholar
• Trapero A , González-BulnesP, ButtersTDet al. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease. J. Med. Chem. 55 (9), 4479–4488 (2012).
   PubMed Web of Science ®Google Scholar
• Suzuki Y , IchinomiyaS, KurosawaMet al. Therapeutic chaperone effect of N-octyl-4-epi-β-valienamine on murine G(M1)-gangliosidosis. Mol. Genet. Metab. 106 (1), 92–98. (2012).
   PubMed Web of Science ®Google Scholar
• Takai T , HigakiK, Aguilar-MoncayoMet al. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol. Ther. 21 (3), 526–532 (2013).
   PubMed Web of Science ®Google Scholar
• Okumiya T , KroosMA, VlietLVet al. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol. Genet. Metab. 90 (1), 49–57 (2007).
   PubMed Web of Science ®Google Scholar
• Parenti G , ZuppaldiA, Gabriela PittisMet al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol. Ther. 15 (3), 508–514 (2007).
   Web of Science ®Google Scholar
• Flanagan JJ , RossiB, TangKet al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum. Mutat. 30 (12), 1683–1392 (2009).
   PubMed Web of Science ®Google Scholar
• Xiao J , WestbroekW, MotabarOet al. Discovery of a novel noniminosugar acid α-glucosidase chaperone series. J. Med. Chem. 55 (17), 7546–7559 (2012).
   PubMed Web of Science ®Google Scholar
• Rajan Rs , TsumotoK, TokunagaMet al. Chemical and pharmacological chaperones: application for recombinant protein production and protein folding diseases. Curr. Med. Chem. 18 (1), 1–15 (2011).
   PubMed Web of Science ®Google Scholar
• Lieberman Rl , D’aquinoJ A, RingeDet al. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48 (22), 4816–4827 (2009).
   PubMed Web of Science ®Google Scholar
• Naik S , ZhangN, GaoPet al. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases. Curr. Top. Med. Chem. 12 (22), 2504–2522 (2012).
   PubMed Web of Science ®Google Scholar
• Tropak MB , KornhaberGJ, RigatBAet al. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem 9 (16), 2650–2662 (2008).
   PubMed Web of Science ®Google Scholar
• Luan Z , LiL, NinomiyaHet al. The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases. Blood Cells Mol. Dis. 44 (1), 48–54 (2010).
   PubMed Web of Science ®Google Scholar
• Goddard-Borger Ed , TropakMb, YonekawaSet al. Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. J. Med. Chem.55 (6), 2737–2745 (2012).
   PubMed Web of Science ®Google Scholar
• Li ZH , LiTH, DaiSXet al. New insights into the pharmacological chaperone activity of C2-Substituted glucoimidazoles for the treatment of Gaucher disease. ChemBioChem 14 (10), 1239–1247 (2013).
   PubMed Web of Science ®Google Scholar
• Guce AI , ClarkNE, RogichJJet al. The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem. Biol. 18 (12), 1521–1526 (2011).
   PubMedGoogle Scholar
• Porto C , PisaniA, RosaMet al. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J. Inherit. Metab. Dis. 35 (3), 513–520 (2012).
   PubMed Web of Science ®Google Scholar
• Brumshtein B , GreenblattHM, ButtersTDet al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J. Biol. Chem.282 (39), 29052–29058 (2007).
   PubMed Web of Science ®Google Scholar
• Clark Ne , MetcalfMc, BestDet al. Pharmacological chaperones for human alpha-N-acetylgalactosaminidase. Proc. Natl Acad. Sci. USA 109 (43), 17400–17405 (2012).
   PubMed Web of Science ®Google Scholar
• Boyd Re , LeeG, RybczynskiPet al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J. Med. Chem. 56 (7), 2705–2725 (2013).
   PubMed Web of Science ®Google Scholar
• Sawkar Ar , Adamski-WernerSl, ChengWcet al. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 12 (11), 1235–1244 (2005).
   PubMedGoogle Scholar
• Wei Rr , HughesH, BoucherSet al. X-ray and biochemical analysis of N370S mutant human acid beta-glucosidase. J. Biol. Chem. 286 (1), 299–308 (2011).
   PubMed Web of Science ®Google Scholar
• Parenti G , PignataC, VajroPet al. New strategies for the treatment of lysosomal storage diseases. Int. J. Mol. Med. 31 (1), 11–20 (2013).
   PubMed Web of Science ®Google Scholar
• Boelens JJ , PrasadVK, TolarJet al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr. Clin. North Am. 57 (1), 123–145 (2010).
   PubMed Web of Science ®Google Scholar
• Desnick RJ , SchuchmanEH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet.13, 307–335 (2012).
   PubMed Web of Science ®Google Scholar
• van Gelder CM , VollebregtAA, PlugIet al. Treatment options for lysosomal storage disorders: developing insights. Expert Opin. Pharmacother. 13 (16), 2281–2299 (2012).
   PubMed Web of Science ®Google Scholar
• Sands MS , DavidsonBL. Gene therapy for lysosomal storage diseases. Mol. Ther.13 (5), 839–849 (2006).
   PubMed Web of Science ®Google Scholar
• Byrne BJ , FalkDJ, ClémentNet al. Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum. Gene Ther. 23 (8), 808–815 (2012).
   PubMed Web of Science ®Google Scholar
• Platt FM , JeyakumarM. Substrate reduction therapy. Acta Paediatr. Suppl.97 (457), 88–93 (2008).
   Google Scholar
• Lachmann RH . Enzyme replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr.23 (6), 588–593 (2011).
   PubMed Web of Science ®Google Scholar
• Wyatt K , HenleyW, AndersonLet al. The effectiveness and cost–effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol. Assess. 16 (39), 1–543 (2012).
   PubMed Web of Science ®Google Scholar
• Huynh HT , GrubbJH, VoglerCet al. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA 109 (42), 17022–17027 (2012).
   PubMed Web of Science ®Google Scholar
• Boado RJ , HuiEK, LuJZet al. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol. Pharm. 8 (4), 1342–1350 (2011).
   PubMed Web of Science ®Google Scholar
• Treiber A , MorandO, ClozelM. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica37 (3), 298–314 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki Y , IchinomiyaS, KurosawaMet al. Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis. Ann. Neurol. 62 (6), 671–675 (2007).
   PubMed Web of Science ®Google Scholar
• Schueler UH , KolterT, KaneskiCRet al. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J. Inherit. Metab. Dis.27 (5), 649–658 (2004).
   PubMed Web of Science ®Google Scholar
• Cardone M , PortoC, TaralloAet al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1 (1), 6 (2008).
   PubMedGoogle Scholar
• Khanna R , SoskaR, LunYet al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol. Ther. 18 (1), 23–33 (2010).
   PubMed Web of Science ®Google Scholar
• Patnaik S , ZhengW, ChoiJHet al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55 (12), 5734–5748 (2012).
   PubMed Web of Science ®Google Scholar
• Rogers S , PatnaikS, SchoenenFet al. Discovery, SAR, and biological evaluation of non-inhibitory chaperones of glucocerebrosidase. In :  Probe Reports from the NIH Molecular Libraries Program.National Center for Biotechnology Information, MD, USA  (2010). www.ncbi.nlm.nih.gov/books/NBK143537
   Google Scholar
• Zheng W , PadiaJ, UrbanDjet al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl Acad. Sci. USA 104 (32), 13192–13197 (2007).
   PubMed Web of Science ®Google Scholar
• Urban DJ , ZhengW, Goker-AlpanOet al. Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening. Comb. Chem. High Throughput Screen. 11 (10), 817–824 (2008).
   PubMed Web of Science ®Google Scholar
• Motabar O , ShiZD, GoldinEet al. A new resorufin-based alpha-glucosidase assay for high-throughput screening. Anal. Biochem. 390 (1), 79–84 (2009).
   PubMed Web of Science ®Google Scholar
• Marugan J , ZhengW, FerrerMet al. Discovery, SAR, and biological evaluation of a non-inhibitory chaperone for acid alpha glucosidase. In :  Probe Reports from the NIH Molecular Libraries Program.National Center for Biotechnology Information, MD, USA  (2010). www.ncbi.nlm.nih.gov/books/NBK153221
   Google Scholar
• Tropak MB , BlanchardJE, WithersSGet al. High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem. Biol. 14 (2), 153–164 (2007).
   PubMedGoogle Scholar
• Guce AI , ClarkNE, SalgadoENet al. Catalytic mechanism of human alpha-galactosidase. J. Biol. Chem. 285 (6), 3625–3632 (2010).
   PubMed Web of Science ®Google Scholar
• Landon MR , LiebermanRL, HoangQQet al. Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J. Comput. Aided Mol. Des. 23 (8), 491–500 (2009).
   PubMed Web of Science ®Google Scholar
• Porto C , FerraraMC, MeliMet al. Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine. Mol. Ther.20 (12), 2201–2211 (2012).
   PubMed Web of Science ®Google Scholar
• Xu YH , PonceE, SunYet al. Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr. Res.39 (2), 313–322 (1996).
   PubMed Web of Science ®Google Scholar
• Khanna R , FlanaganJJ, FengJet al. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS ONE7 (7), e40776 (2012).
   Web of Science ®Google Scholar
• Fukuda T , AhearnM, RobertsAet al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 14 (6), 831–839 (2006).
   PubMed Web of Science ®Google Scholar
• Shen JS , EdwardsNJ, HongYBet al. Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem. Biophys. Res. Commun. 369 (4), 1071–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Porto C , CardoneM, FontanaFet al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol. Ther. 17 (6), 964–971 (2009).
   PubMed Web of Science ®Google Scholar
• Benjamin ER , KhannaR, SchillingAet al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol. Ther. 20 (4), 717–726 (2012).
   PubMed Web of Science ®Google Scholar
• Germain DP , GiuglianiR, HughesDAet al. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two Phase 2 clinical studies. Orphanet J. Rare Dis.7, 91 (2012).
   Google Scholar
• Giugliani R , WaldekS, GermainDPet al. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol. Genet. Metab. 109 (1), 86–92 (2013).
   PubMed Web of Science ®Google Scholar
• Zimran A , AltarescuG, ElsteinD. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis.50 (2), 134–137 (2013).
   PubMed Web of Science ®Google Scholar
• Parenti G , FecarottaS, la MarcaGet al. Achaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol. Ther. (2014) ( In Press).
   PubMed Web of Science ®Google Scholar